scholarly journals Peripheral Blood Eosinophil Count Optimizes Pembrolizumab-Based Immunotherapy in The First-Line Setting of Advanced or Recurrent Non-Small Cell Lung Cancer

2021 ◽  
Author(s):  
Mao Uematsu ◽  
Kosuke Narita ◽  
Taro Sato ◽  
Yukio Hosomi
Keyword(s):  
Lung Cancer ◽  
Peripheral Blood ◽  
Eosinophil Count ◽  
Small Cell ◽  
Blood Eosinophil ◽  
Small Cell Lung ◽  
First Line ◽  
Peripheral Blood Eosinophil ◽  
Blood Eosinophil Count ◽  
Line Setting

Abstract For cancer immunotherapy, the tumor proportion score for the programmed death-1 ligand is not a robust biomarker. The peripheral blood eosinophil count (PEC) is a potential alternative. However, it is not yet established. To test the efficacy of PEC-guided selection of pembrolizumab monotherapy (MONO) or pembrolizumab plus chemotherapy (COMBO), we retrospectively reviewed data of patients with advanced or recurrent non-small cell lung cancer in the first-line setting (April 2017 to April 2020). Among 137 patients enrolled, Kaplan–Meier analysis revealed no significant difference between the MONO (n = 84) and COMBO (n = 53) therapies. The influence of PEC before the second administration of each regimen (PEC2) was evaluated. The low PEC2 subgroup (<150 × 106/L) receiving MONO had poorer survival rates than those receiving COMBO (median progression-free survival [mPFS]: 5.75 vs. 7.59 months and median overall survival [mOS]: 12.0 months vs. not reached [NR), respectively). In patients receiving MONO, the low PEC2 showed worse prognosis compared with the high PEC2 group (mPFS: 5.75 vs. 16.1 months and mOS: 12.0 months vs. NR, respectively). PEC2 can be a potential predictive/prognostic biomarker for MONO, which encourages the switch from MONO to COMBO to avoid treatment failure.

Peripheral blood eosinophil count correlates with survival in lung cancer

Lung Cancer ◽  
2010 ◽  
Vol 67 ◽  
pp. S40-S41 ◽  
Author(s):  
A. Shelton ◽  
R.H. Green ◽  
P. Bradding ◽  
C.M. Free
Keyword(s):  
Lung Cancer ◽  
Peripheral Blood ◽  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Peripheral Blood Eosinophil ◽  
Blood Eosinophil Count

Evaluation of the peripheral blood eosinophil count as a predictor for fractional exhaled nitric oxide or bronchodilator reversibility test outcome

2021 ◽  
Vol 42 (3) ◽  
pp. 228-234
Author(s):  
Bo Zhao ◽  
Haiming Zheng ◽  
Xiaopan Li ◽  
Rui Zheng
Keyword(s):  
Nitric Oxide ◽  
Roc Curve ◽  
Peripheral Blood ◽  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Test Results ◽  
Fractional Exhaled Nitric Oxide ◽  
Peripheral Blood Eosinophil ◽  
Blood Eosinophil Count ◽  
Feno Level

Objective: This study aimed to explore the usefulness of the peripheral blood eosinophil count (PBEC) in assessing the level of fractional exhaled nitric oxide (FeNO) and predicting bronchodilation test results. Methods: We retrospectively analyzed the data of 384 outpatients who underwent FeNO measurement at our Department of Respiratory and Critical Care Medicine from March to June 2019. The FeNO level was compared among different PBECs to explore the association among them. Furthermore, the sensitivity and specificity of PBECs in predicting bronchodilation test results were assessed by using receiver operating characteristic (ROC) curve analysis. Results: There was a moderate correlation between PBECs and FeNO levels (r = 0.414; p < 0.05). In the subjects with PBECs ≥ 0.3 × 109/L, the median FeNO level was 39 ppb (interquartile range, 22.5‐65.5 ppb), significantly higher than in the subjects with PBECs < 0.3 × 109/L. The area under the ROC curve was 0.707 (p < 0.05). The maximum Youden index (0.348) was at PBECs = 0.205 × 109/L, which achieved sensitivity and specificity of 63% and 71.8%, respectively. Conclusion: PBECs ≥ 0.3 × 109/L can predict a positive bronchodilation test result and a high FeNO level, with a probability of 50% in the subjects with chronic cough and shortness of breath; in the absence of corresponding symptoms and a low PBEC, the predictive value was small. For hospitals not able to conduct FeNO measurements, for outpatients with poor economic conditions, and for patients with confirmed or suspected novel coronavirus disease 2019, the PBEC, in conjunction with a patient's clinical symptoms, can improve the diagnostic accuracy of allergic asthma and assessment of airway inflammation while reducing the risk of infection.

scholarly journals Angiogenesis Inhibitors in Small Cell Lung Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Agnese Montanino ◽  
Anna Manzo ◽  
Guido Carillio ◽  
Giuliano Palumbo ◽  
Giovanna Esposito ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Biomarkers ◽  
Angiogenesis Inhibitors ◽  
Small Cell ◽  
Chinese Patients ◽  
Small Cell Lung ◽  
First Line ◽  
Line Setting

Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung cancer (SCLC). Bevacizumab, a monoclonal antibody directed against VEGF, showed a promising activity in combination with etoposide and cisplatin as first-line treatment of patients with extended stage (ES)-SCLC and two randomized studies confirmed that bevacizumab improved PFS, but failed to prolong OS. Instead, disappointing results have been observed with endostar, sunitinib, sorafenib, vandetanib, and thalidomide in combination with chemotherapy in the first-line setting, with sunitinib in the maintenance setting, with sunitinib, cediranib and nintedanib as single agents or ziv-aflibercept in combination with topotecan in second-line setting. Only anlotinib improved OS and PFS as third-line therapy in Chinese patients with SCLC, and it was approved with this indication in China. Future challenges are the evaluation of the role of angiogenesis inhibitors in combination with immune- checkpoint inhibitors and chemotherapy in SCLC patients and the identification of predictive biomarkers of response to both agents.

Sign in / Sign up

Export Citation Format

Share Document